Showing results (1-10 of 67) with videos related to
Sort By:
Pageof 7
Neuroendocrinology|May 27, 2003
Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male miceAndres D Ramirez, Xingrong Liu, Frank S MennitiNature Reviews. Drug Discovery|August 3, 2006
Phosphodiesterases in the CNS: targets for drug developmentFrank S Menniti, W Stephen Faraci, Christopher J SchmidtFrontiers in Neuroscience|September 12, 2019
Phosphodiesterase 9A in Brain Regulates cGMP Signaling Independent of Nitric-OxideJohn F Harms, Frank S Menniti, Christopher J SchmidtFrontiers in Neuroscience|February 8, 2021
PDE10A Inhibitors-Clinical Failure or Window Into Antipsychotic Drug Action?Frank S Menniti, Thomas A Chappie, Christopher J SchmidtAnnals of the New York Academy of Sciences|March 11, 2015
Translational psychiatry--light at the end of the tunnelKenneth A Jones, Frank S Menniti, Digavalli V SivaraoCells|July 26, 2024
A Novel PDE10A Inhibitor for Tourette Syndrome and Other Movement DisordersRandall D Marshall, Frank S Menniti, Mark A TepperNeuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|September 26, 2015
Differential Effects of an NR2B NAM and Ketamine on Synaptic Potentiation and Gamma Synchrony: Relevance to Rapid-Onset Antidepressant EfficacyDávid Nagy, Milan Stoiljkovic, Frank S Menniti, et al.European Journal of Pharmacology|September 5, 2003
Pramipexole inhibits MPTP toxicity in mice by dopamine D3 receptor dependent and independent mechanismsAndres D Ramirez, Stephen K-F Wong, Frank S MennitiExpert Opinion on Therapeutic Targets|July 26, 2013
PDE4 as a target for cognition enhancementWito Richter, Frank S Menniti, Han-Ting Zhang, et al.Current Opinion in Investigational Drugs (London, England : 2000)|February 1, 2007
Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophreniaFrank S Menniti, Thomas A Chappie, John M Humphrey, et al.Pageof 7